

AMENDMENTS TO THE CLAIMS

1. (currently amended) A method to treat hyperactive sebaceous gland disorders, other than acne, in a subject by which method comprises:

(i) topically applying a hydrophobic and/or lipophilic photosensitizer composition to skin tissue exhibiting symptoms of ~~a~~ a hyperactive sebaceous gland disorder, and

(ii) exposing the tissue of said subject to light energy at a wavelength capable of activating the photosensitizer and at a fluence rate between about 0.1 mW/cm² and about 600mW/cm²,

wherein said photosensitizer is other than 5-aminolevulinic acid and derivatives thereof.

2. (currently amended) The method of claim 1, wherein the disorder is ~~selected from acne, seborrhea, seborrheic dermatitis, and or~~ sebaceous gland hyperplasia.

3. (currently amended) The method of claim 1, wherein the photosensitizer is ~~selected from a lipophilic photosensitizers~~ photosensitizer.

4. (currently amended) The method of claim 1, wherein the photosensitizer is ~~selected from a hydrophobic photosensitizers~~ photosensitizer.

5. (currently amended) The method of claim 1, wherein the photosensitizer is ~~selected from 5-aminolevulinic acid and derivatives thereof, 5-aminolevulinic acid esters and derivatives thereof, porphyrins and derivatives~~ (a) a porphyrin or derivative thereof, (b) a methylene blue and derivatives or derivative thereof, (c) a bacteriochlorophyll and derivatives or derivative thereof, and combinations or a combination of any of (a) - (c) thereof.

6. (currently amended) The method of claim 1, wherein the photosensitizer is ~~selected from the group consisting of 5-aminolevulinic acid, 5-aminolevulinic acid esters, chlorins, bacteriochlorins, isobacteriochlorins, phthalocyanine, naphthalocyanines, pyropheophorbides,~~

~~sapphyrins, texaphyrins, tetrahydrochlorins, purpurins, porphycenes, phenothiaziniums, bacteriochlorophyll, bacteriochlorophyll derivatives, pro-porphyrins, porphyrins, and combinations thereof~~ (a) a chlorin, (b) a bacteriochlorin, (c) a isobacteriochlorin, (d) a phthalocyanine, (e) a naphthalocyanine, (f) a pyropheophorbide, (g) a sapphyrin, (h) a texaphyrin, (i) a tetrahydrochlorin, (j) a purpurin, (k) a porphycene, (l) a phenothiazinium, (m) a bacteriochlorophyll, (n) a bacteriochlorophyll derivative, (o) a pro-porphyrin, (p) a porphyrin, or a combination of any of (a) - (p).

7. (currently amended) The method of claim 1, wherein the photosensitizer is ~~selected from the group consisting of~~ (a) a verteporfin, (b) a lemuteporfin, and combinations thereof or a combination of (a) and (b).

8. (previously presented) The method of claim 1, wherein the composition has a viscosity at 20°C of from about 50 cps to about 50000 cps.

9. (previously presented) The method of claim 1, wherein excess photosensitizer composition is removed from the skin prior to application of activation energy.

10. (canceled)

11. (currently amended) The method of claim 1, wherein steps i) and ii) are repeated at least about once every six months.

12. (currently amended) The method of claim 1, wherein steps i) and ii) are repeated at least about once every three months.

13. (currently amended) The method of claim 1, wherein steps (i) and (ii) are repeated at intervals of not less than about 5 days.

14. (currently amended) The method of claim 1, wherein ~~the hyperactive sebaceous gland disorder is acne and~~ the method further ~~includes~~ comprises at least one non-photodynamic treatment for ~~acne~~ hyperactive sebaceous gland disorder.

15. (previously presented) The method of claim 14, wherein the non-photodynamic treatment is at least one topical treatment.

16. (previously presented) The method of claim 14, wherein the non-photodynamic treatment is administering one or more agents selected from the group consisting of topical retinoids, oral retinoids, systemic antibiotics, topical or local antibodies, oral contraceptives, topical anti-androgens, anti-progestins, blue light therapy, laser therapy, and combinations thereof.

17. (previously presented) The method of claim 14, wherein the non-photodynamic treatment comprises administering one or more topical retinoids:

18. (previously presented) The method of claim 1, wherein said energy is at least in part supplied by a light emitting diode device.

19. (previously presented) The method of claim 18, wherein said device emits red and blue light.

20-21. (canceled)

22. (new) The method of claim 7, wherein the photosensitizer is lemuteporfin.